down arrow

Johnson & Johnson

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4781601046
USD
202.48
-2.85 (-1.39%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

201.72204.75

52 Week

140.68207.81
Valuation
Technical
Day's Volume

CASH

2.76 M

Shareholding (Mar 2025)

FII

16.90%

Held by 709 FIIs

DII

57.27%

Held by 209 DIIs

Promoter

0.10%

How big is Johnson & Johnson?

22-Jun-2025

As of Jun 18, Johnson & Johnson has a market capitalization of $440.9 billion, with net sales of $89.3 billion and a net profit of $21.8 billion for the latest four quarters. The balance sheet shows shareholder's funds of $71.5 billion and total assets of $180.1 billion.

As of Jun 18, Johnson & Johnson has a market capitalization of 440,901.05 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the company reported net sales of 89,331.00 million and a net profit of 21,810.00 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 71,490.00 million and total assets amounting to 180,104.00 million.

Read More

What does Johnson & Johnson do?

22-Jun-2025

Johnson & Johnson is a large-cap holding company focused on healthcare products, including pharmaceuticals and biotechnology, with recent net sales of $21.9 billion and a market cap of $440.9 billion. Key financial metrics include a P/E ratio of 23.00 and a dividend yield of 2.96%.

Overview:<BR>Johnson & Johnson is a holding company engaged in the research and development, manufacture, and sale of a range of healthcare products, operating in the Pharmaceuticals & Biotechnology industry with a large-cap market presence.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 21,894 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 10,999 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 440,901.05 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 23.00 <BR>Dividend Yield: 2.96% <BR>Debt Equity: 0.17 <BR>Return on Equity: 25.13% <BR>Price to Book: 5.64<BR><BR>Contact Details:<BR>Address: 1 Johnson And Johnson Plz, NEW BRUNSWICK NJ: 08933-0001 <BR>Tel: ['1 732 5242455', '1 800 9505089'] <BR>Fax: 1 732 2140332 <BR>Website: https://www.jnj.com/

Read More

Who are in the management team of Johnson & Johnson?

22-Jun-2025

As of March 2022, Johnson & Johnson's management team includes Chairman and CEO Alex Gorsky and Lead Independent Director Anne Mulcahy, along with Independent Directors Dr. Mary Beckerle, Mr. D. Scott Davis, Mr. Ian Davis, and Dr. Jennifer Doudna.

As of March 2022, the management team of Johnson & Johnson includes Mr. Alex Gorsky, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, Ms. Anne Mulcahy is the Lead Independent Director. The board also comprises several Independent Directors: Dr. Mary Beckerle, Mr. D. Scott Davis, Mr. Ian Davis, and Dr. Jennifer Doudna.

Read More

Is Johnson & Johnson overvalued or undervalued?

20-Sep-2025

As of July 16, 2025, Johnson & Johnson's valuation has shifted from very attractive to attractive, with a current P/E ratio of 23, outperforming the S&P 500 year-to-date with a 20.43% return, but lagging behind over the past 3 and 5 years.

As of 16 July 2025, the valuation grade for Johnson & Johnson has moved from very attractive to attractive, indicating a shift in perceived value. The company is currently considered fairly valued. Key valuation ratios include a P/E ratio of 23, an EV to EBITDA of 16.16, and a Price to Book Value of 5.74. In comparison, Eli Lilly & Co. has a higher P/E of 40.89, while Merck & Co., Inc. shows a more attractive P/E of 15.68.<BR><BR>Despite the recent downgrade in valuation, Johnson & Johnson has outperformed the S&P 500 year-to-date with a return of 20.43% compared to the index's 12.22%. However, over longer periods, such as the 3-year and 5-year returns, the company has lagged behind the S&P 500, with returns of 3.91% and 16.74% respectively, compared to the index's 70.41% and 96.61%.

Read More

Is Johnson & Johnson technically bullish or bearish?

20-Sep-2025

As of July 24, 2025, Johnson & Johnson's technical trend is bullish, supported by positive MACD and moving averages, despite mixed signals from Dow Theory and OBV, and while it has underperformed the S&P 500 recently, it has outperformed year-to-date.

As of 24 July 2025, the technical trend for Johnson & Johnson has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, supporting the positive trend. Daily moving averages also indicate a bullish stance. However, the weekly Dow Theory shows a mildly bearish signal, and the On-Balance Volume (OBV) is mildly bearish on a weekly basis but bullish monthly. <BR><BR>In terms of performance, Johnson & Johnson has underperformed the S&P 500 over the past week and month, with returns of -2.43% and -1.19% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has outperformed the benchmark with a return of 20.43% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish, albeit with some mixed signals from certain indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 432,803.06%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.26 times

 
3

Poor long term growth as Operating profit has grown by an annual rate 0.96% of over the last 5 years

 
4

Flat results in Jun 25

5

With ROCE of 23.24%, it has a very attractive valuation with a 5.05 Enterprise value to Capital Employed

6

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 515,810 Million (Large Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.56%

stock-summary
Debt Equity

0.41

stock-summary
Return on Equity

25.10%

stock-summary
Price to Book

6.57

Revenue and Profits:
Net Sales:
23,741 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,537 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.27%
0%
13.27%
6 Months
32.15%
0%
32.15%
1 Year
34.57%
0%
34.57%
2 Years
27.44%
0%
27.44%
3 Years
13.19%
0%
13.19%
4 Years
27.04%
0%
27.04%
5 Years
34.74%
0%
34.74%

Johnson & Johnson for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Johnson & Johnson Hits New 52-Week High at USD 190.22

Johnson & Johnson Hits New 52-Week High at USD 190.22

Johnson & Johnson achieved a new 52-week high of USD 190.22 on October 8, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a solid market capitalization and favorable financial metrics, indicating effective resource management.

Read More
Johnson & Johnson Hits New 52-Week High at $189.92, Showcasing Strong Growth

Johnson & Johnson Hits New 52-Week High at $189.92, Showcasing Strong Growth

Johnson & Johnson achieved a new 52-week high of USD 189.92 on October 6, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a notable stock price increase over the past year, supported by solid financial metrics and a substantial market capitalization.

Read More
Johnson & Johnson Hits New 52-Week High at USD 189.78

Johnson & Johnson Hits New 52-Week High at USD 189.78

Johnson & Johnson achieved a new 52-week high of USD 189.78 on October 3, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a solid market capitalization and favorable financial metrics, indicating effective resource management and profitability.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.39%
EBIT Growth (5y)
0.96%
EBIT to Interest (avg)
24.32
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.81
Tax Ratio
17.14%
Dividend Payout Ratio
84.80%
Pledged Shares
0
Institutional Holding
74.50%
ROCE (avg)
432,803.06%
ROE (avg)
387,416.25%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
5.74
EV to EBIT
21.71
EV to EBITDA
16.16
EV to Capital Employed
5.05
EV to Sales
5.17
PEG Ratio
NA
Dividend Yield
2.91%
ROCE (Latest)
23.24%
ROE (Latest)
25.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 304 Schemes (25.69%)

Foreign Institutions

Held by 709 Foreign Institutions (16.9%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 8.44% vs -2.78% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -49.66% vs 220.58% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23,741.00",
          "val2": "21,894.00",
          "chgp": "8.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,782.00",
          "val2": "8,069.00",
          "chgp": "8.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "432.00",
          "val2": "287.00",
          "chgp": "50.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-450.00",
          "val2": "6,820.00",
          "chgp": "-106.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,537.00",
          "val2": "10,999.00",
          "chgp": "-49.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "288.10%",
          "val2": "287.60%",
          "chgp": "0.05%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.31% vs 6.36% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.55% vs -18.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "88,819.00",
          "val2": "85,152.00",
          "chgp": "4.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28,162.00",
          "val2": "29,648.00",
          "chgp": "-5.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1,150.00",
          "val2": "1,177.00",
          "chgp": "-2.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6,241.80",
          "val2": "-9,309.30",
          "chgp": "32.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "14,066.00",
          "val2": "13,326.00",
          "chgp": "5.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "234.40%",
          "val2": "260.30%",
          "chgp": "-2.59%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
23,741.00
21,894.00
8.44%
Operating Profit (PBDIT) excl Other Income
8,782.00
8,069.00
8.84%
Interest
432.00
287.00
50.52%
Exceptional Items
-450.00
6,820.00
-106.60%
Consolidate Net Profit
5,537.00
10,999.00
-49.66%
Operating Profit Margin (Excl OI)
288.10%
287.60%
0.05%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 8.44% vs -2.78% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -49.66% vs 220.58% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
88,819.00
85,152.00
4.31%
Operating Profit (PBDIT) excl Other Income
28,162.00
29,648.00
-5.01%
Interest
1,150.00
1,177.00
-2.29%
Exceptional Items
-6,241.80
-9,309.30
32.95%
Consolidate Net Profit
14,066.00
13,326.00
5.55%
Operating Profit Margin (Excl OI)
234.40%
260.30%
-2.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 4.31% vs 6.36% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 5.55% vs -18.59% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Johnson & Johnson stock-summary
stock-summary
Johnson & Johnson
Pharmaceuticals & Biotechnology
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Company Coordinates stock-summary
Company Details
1 Johnson And Johnson Plz , NEW BRUNSWICK NJ : 08933-0001
stock-summary
Tel: 1 732 52424551 800 9505089
stock-summary
https://www.jnj.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."